
























































































































































































































A/A	 	 	 	 	 Antibiotic	antimycotic	
AML	 	 	 	 	 Acute	myeloid	leukemia	
AP-1	 	 	 	 	 Activator	protein-1	
APC	 	 	 	 	 Antigen	Presenting	Cell	
APS	 	 	 	 	 Ammonium	Persulfate	
ATCC	 	 	 	 	 American	Tissue	Culture	Collection	
BC	 	 	 	 	 Breast	cancer	
BCA	 	 	 	 	 Bicinchoninic	acid	
BCCL	 	 	 	 	 Breast	cancer	cell	lines	
BID	 	 	 	 	 Bi-daily	
BSA	 	 	 	 	 Bovine	serum	albumin	
CDFBS	 	 	 	 	 Charcoal/dextran	fetal	bovine	serum	
CIITA	 	 	 	 	 Class	II	Transactivator	
CLIP	 	 	 	 	 Class	II	associated	Ii	peptide	
CM	 	 	 	 	 Complete	media	
CREB	 	 	 	 	 cAMP	response	element-binding	
CTL	 	 	 	 	 Cytotoxic	T	lymphocytes	
DC	 	 	 	 	 Dendritic	cells	
DMSO	 	 	 	 	 Dimethyl	sulfoxide	
E	 	 	 	 	 Glutamic	acid	
E2	 	 	 	 	 Estradiol	
EDTA	 	 	 	 	 Ethylene-diaminetetraaccetic	acid	
EGF	 	 	 	 	 Epidermal	growth	factor	
ER	 	 	 	 	 Endoplasmic	reticulum	
ERK	 	 	 	 	 Extracellular	signal-regulated	protein	kinases	
ERα	 	 	 	 	 Estrogen	receptor	alpha	
ERβ	 	 	 	 	 Estrogen	receptor	beta	
ESCC																																																									Esophageal	squamous	cell	carcinoma	
FBS	 	 	 	 	 Fetal	bovine	serum	
GAM	 	 	 	 	 Goat	anti	mouse	
GAPDH	 	 	 	 Glyceraldehyde	3-phosphate	dehydrogenase	
GAR	 	 	 	 	 Goat	anti	rabbit	
GDP	 	 	 	 	 Guanine	diphosphate	
GTP	 	 	 	 	 Guanine	triphosphate	
HEPES	 	 	 	 	 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic	acid	
HER2	 	 	 	 	 Human	epidermal	growth	factor	
HLA	 	 	 	 	 Human	leukocyte	antigen	
Hr	 	 	 	 	 Hour	
ICAM-1	 	 	 	 Intercellular	adhesion	molecule	1	
IFN-γ	 	 	 	 	 Interferon	gamma	
IFNGR	 	 	 	 	 Interferon	gamma	receptor	
	 ix	
Ii	 	 	 	 	 Invariant	chain	
IL	 	 	 	 	 Interleukin	
IMDM	 	 	 	 	 Iscove’s	modified	Dulbecco’s	medium	
IRF	 	 	 	 	 Interferon	regulatory	factor	
IRF-E	 	 	 	 	 IFN-regulatory	factor	element	
ISRE	 	 	 	 	 Interferon-sensitive	response	element	
ITIM	 	 	 	 	 Immunoreceptor	tyrosine-based	inhibitory	motif	
ITSM	 	 	 	 	 Immunoreceptor	tyrosine-based	switch	receptor	
JAK	 	 	 	 	 Janus	activating	kinases	
JNK	 	 	 	 	 c-Jun	N-terminal	kinases	
K	 	 	 	 	 Lysine	
Kb	 	 	 	 	 Kilobase	
kDa	 	 	 	 	 Kilo	Dalton	
MAP-K2	 	 	 	 MAPK-activated	protein	kinase-2	
MAPK	 	 	 	 	 Mitogen-activated	protein	kinase		
MAPKAP	 	 	 	 MAPK-activated	protein	kinase	
ME	 	 	 	 	 Mercaptoethanol	
MEK	1	 	 	 	 	 MAPK/ERK	kinase	1	
MEKK	 	 	 	 	 MEK	kinase	
MEM	 	 	 	 	 Minimum	essential	medium	
MFI	 	 	 	 	 Mean	fluorescence	intensity	
MHC	 	 	 	 	 Major	histocompatibility	complex	
MIIC	 	 	 	 	 MHC	class	II	loaded	compartments	
Min	 	 	 	 	 Minute	
MIP-1α	 	 	 	 Macrophage	inflammatory	protein-1	alpha	
MKK6	 	 	 	 	 MAPK	kinase	6	
NAC	 	 	 	 	 Neoadjuvant	chemotherapy	
NF-Y	 	 	 	 	 Nuclear	transcription	factor	Y	
NF-κβ	 	 	 	 	 Nuclear	factor	kappa-light-chain-enhancer	of		
	 	 	 	 	 activated	B	cells	
NK	 	 	 	 	 Natural	killer	
NKT	 	 	 	 	 Natural	killer	T	cells	
NSCLC	 	 	 	 	 Non-small-cell	lung	carcinoma	
PAGE	 	 	 	 	 Polyacrylamide	gel	
PBS	 	 	 	 	 Phosphate	buffer	saline	
pCR	 	 	 	 	 Pathological	complete	response	
PD-L1	 	 	 	 	 Programmed	cell	death	ligand-1	
pI,	pII,	pIII,	pIV		 	 	 CIITA	promoters	1-4	
PI3-K	 	 	 	 	 Phosphoinositide-3-kinase	
PKC	 	 	 	 	 Protein	kinase	C	
PMSF	 	 	 	 	 Phenylmethylsulfonyl	fluoride	
PR	 	 	 	 	 Progesterone	receptor	
PTEN	 	 	 	 	 Phosphatase	and	tensin	homolog	
RIPA	 	 	 	 	 Radioimmunoprecipitation	assay	
	 x	
RT-PCR	 	 	 	 Reverse	transcriptase	polymerase	chain	reaction	
Sel	 	 	 	 	 Selumetinib	
SEM	 	 	 	 	 Standard	errors	of	the	mean	
SH2	 	 	 	 	 Src	homology	2	
Shp2	 	 	 	 	 SH2-containg	tyrosine	phosphatase-2	
siRNA	 	 	 	 	 Small	interfering	RNA	
SOS	 	 	 	 	 Son	of	sevenless	
STAT	 	 	 	 	 Signal	transducer	and	activator	of	transcription	
TAP	 	 	 	 	 Transporter	associated	with	antigen	processing	
TBS	 	 	 	 	 Tris-buffered	saline	
TCR	 	 	 	 	 T	cell	receptor	
TEMED	 	 	 	 Tetramethylethylenediamine	
TGF-β	 	 	 	 	 Transforming	growth	factor	beta	
Th1	 	 	 	 	 T	helper	type	1	
TIL	 	 	 	 	 Tumour	infiltrating	lymphocytes	
TNBC	 	 	 	 	 Triple	negative	breast	cancer	cells	
TNF-α	 	 	 	 	 Tumour	necrosis	factor	alpha	
Tram	 	 	 	 	 Trametinib	
V	 	 	 	 	 Valine	
WB	 	 	 	 	 Washing	buffer	


























































































































































































































































































































































































































































































Reduced TCR Signaling 
Reduced cytokine production 
Reduced target cell lysis 





































































































































































































































































































































































































































































































































Mouse	IgG2a	 HLA	class	I	 1/25	 1/25	 1/25	 In	house	
MUB2037P	 Mouse	IgG2a	 HLA	class	I	
heavy	chain		
NA3	 1/1000	 NA	 Nordic	MUbio	
L243	
	
Mouse	IgG2a	 HLA-DR	 2.5	µg/ml	 NA	 2.5	µg/ml	 In	house	
MIH2	
ab109052	




Rabbit	IgG	 PD-L1	 NA	 1/1000	 	 Cell	Signaling		
	

















Rabbit	IgG	 ERK-1	total	 NA	 1/5000	 NA	 SantaCruz	
Biotechnology	
	





Control	 5	µg/ml	 NA	 5µg/ml	 Local	source	
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Figure	3.16:	Western	blot	of	whole	cell	lysates	from	time	response	of	MDA-MB-435	
cells.	
Cells	were	treated	with	Selumetinib	(S)	(10	µM),	Trametinib	(T)	(10	nM),	U0126	(U)	(10	
µM)	or	DMSO	(vehicle	control	(C))	and	induced	or	not	with	IFN-γ	(100	u/ml)	1hr	after	
MEKi	treatment.	A)	MEKi-treated	induced	MDA-MB-435	cells	for	4,	24	and	48hr	time	
points	and	B)	MEKi-treated	induced	and	constitutive	MDA-MB-435	cells	for	48	hours.	
Blots	were	probed	with	PD-L1	(E1L3N),	HLA	class	I	heavy	chain	(MUB2037P),	pERK	
(Thr202/Tyr204),	total	ERK	(K-23)	and	alpha	tubulin	(B-7).	Figure	is	a	representative	
chosen	out	of	3	experiments.			
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Figure	3.17:	Western	blot	data	of	whole	cell	lysates	from	MEKi-treated	MDA-MB-435	
and	HT-29	cells.	
Cells	were	treated	with	Selumetinib	(S)	(10	µM),	Trametinib	(T)	(10	nM),	U0126	(U)	(10	
µM)	or	DMSO	(vehicle	control	(C))	and	induced	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	
treatment	for	a	total	incubation	time	of	72	hours.	Western	blot	analysis	of	MEKi-treated	
A)	MDA-MB-435	and	B)	HT-29	cells.		Blots	were	probed	with	PD-L1	(E1L3N),	HLA	class	I	
heavy	chain	(MUB2037P),	pERK	(Thr202/Tyr204),	total	ERK	(K-23)	and	GAPDH	(AB8245).	
Figure	is	a	representative	chosen	out	of	3	experiments.			
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3.13	Effects	of	MEKi(s)	on	HLA	class	I	and	PD-L1	Expression	in	MDA-MB-435	cells	as	
Determined	by	Immunofluorescence	
	
	 After	obtaining	results	through	flow	cytometry	and	Western	blotting,	we	then	
treated	MDA-MB-435	cells	with	MEKi(s)	and	analyzed	via	immunofluorescence.	Cells	
were	plated	in	8-well	chamber	slides	and	treated	with	U0126	(10	µM),	Selumetinib	(10	
µM)	or	Trametinib	(10	nM)	and	incubated	for	72	hours.	Cells	were	fixed	and	stained	for	
HLA	class	I	and	PD-L1	and	analyzed	on	a	Zeiss	Axiovision	immunofluorescence	
microscope.		
When	treated	with	Tram,	there	appears	to	be	a	higher	intensity	of	HLA	class	I	
expression	while	simultaneously	decreasing	intensity	of	PD-L1	(Figure	3.18),	confirming	
the	results	observed	in	flow	cytometry	analysis	(Figure	3.14	and	3.15)	and	Western	blot	
analysis	(Figure	3.17)	
	
3.14:	U0126	Down-regulates	Surface	HLA	and	PD-L1	Expression	Consistently	Across	all	
Cell	Lines	Tested.	
	 After	the	previous	flow	cytometry	experiments	have	shown	that	treatment	with	
U0126	consistently	decreased	surface	HLA-DR,	HLA	class	I	and	PD-L1	expression	
regardless	of	the	cell	line	used,	a	separate	statistical	analysis	was	used	to	compare	the	
effects	of	each	inhibitor	to	one	another	(chapter	2.5.2).	Results	shown	in	Figure	3.19	
show	that	U0126-treatment	decreased	surface	HLA-DR	expression,	and	its	effect	are	
significantly	different	compared	to	Sel	(Figure	3.19.	A).			 	
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Figure	3.18:	Trametinib	treated	cells	show	increases	in	HLA	class	I	expression	and	
decreases	in	PD-L1	expression.		
Immunofluoresence	of	MDA-MB-435	cells	treated	for	72	hours	with	DMSO	or	
Trametinib	(10	nM)	in	the	presence	of	100	units	IFN-γ.	Cells	were	methanol	
permeabilized	and	paraformaldehyde	fixed,	and	stained	with	primary	antibodies	HLA-DR	
(L243),	HLA	class	I	(w6/32)	and	PD-L1	(E1L3N)	and	then	with	Alexa	Fluor	488	G2A	and	
Alexa	Fluor	555	IgG1	as	secondary	antibodies	with	DAPI	as	blue	nuclear	stain.	
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The	effects	of	U0126	treatment	on	HLA	class	I	are	also	significantly	different	than	
both	Sel	and	Tram	(Figure	3.19.	B),	as	well	as	significantly	different	compared	to	Tram	in	
regards	to	PD-L1	expression	(Figure	3.19.	C).	These	results	show	that	U0126	is	unique	in	
its	effects	on	HLA	and	PD-L1	regulation	as	compared	to	Sel	and	Tram.	
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Figure	3.19:	U0126	modulates	HLA	and	PD-L1	differently	than	other	MEKi(S)	in	all	cell	
lines.	
Compilation	of	MEK-mediated	effects	of	U0126	(10	µM),	Selumetinb	(10	µM)	and	
Trametinib(10	nM)	treatment	in	100u/ml	IFN-γ	induced	MDA-MB-231,	BT-20,	MDA-MB-
468,	MDA-MB-435,	HS578T,	and	HT-29	cells	as	analyzed	by	flow	cytometry	to	
determine:	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Statistical	analysis	was	done	by	Anova	
and	Tukey	HSD	test.	Bar	graphs	represent	mean	MFI.	Asterisks	represent	significance	of	
p	value	<0.05	(*)	and	<0.01	(**).	
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Chapter	4:	Discussion		
	
4.1	Results	Summary	
In	the	course	of	this	research,	we	demonstrated	that	the	MAPK	pathway	plays	a	
role	in	the	regulation	of	the	antigen	presenting	molecules	HLA-DR	and	HLA	class	I,	as	
well	as	the	inhibitory	molecule	PD-L1.	Through	the	use	of	several	MEK	inhibitors	we	
have	shown	that	these	drugs	differentially	affect	HLA	and	PD-L1	expression.	We	
confirmed	previous	research	in	the	Drover	laboratory,	that	U0126-treated	MDA-
231c10A	cells	significantly	decreased	surface	HLA-DR	expression77.	Furthermore,	this	
down-regulation	was	observed	in	other	TNBC	lines:	MDA-MB-231,	BT-20,	MDA-MB-468	
as	well	as	in	the	melanoma	line,	MDA-MB-435,	indicating	that	the	effect	was	not	cell-
context	dependent.		
Due	to	the	differential	effects	of	U0126	and	PD98059	treatment	on	HLA-DR	
expression	in	MDA-231c10A	cells,	we	questioned	what	effects	they	would	have	on	HLA	
class	I,	which	traffics	through	the	endogenous	pathway	(Figure	1.3).	Furthermore	this	
was	of	clinical	relevance	since	HLA	class	I	is	frequently	down-regulated	on	tumor	cells	
thereby	contributing	to	immune	evasion	of	the	tumour26.	We	found	that	U0126	also	
down-regulated	HLA	class	I	and	PD-L1	expression	in	MDA-231c10A	as	well	as	other	TNBC	
and	non-TNBC	lines	showing	a	stark	contrast	in	its	effects	on	HLA	and	PD-L1	modulation	
compared	to	the	other	inhibitors	as	confirmed	in	Figure	3.19.	
Clinically	relevant	MEK	inhibitors	Selumetinib	and	Trametinib	generally	increased	
HLA	class	I	and	decreased	PD-L1	expression	in	the	majority	of	cell	lines	tested	as	
assessed	by	flow	cytometry	and	immunofluorescence,	however	their	effects	on	HLA-DR	
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varied.	Western	blotting	showed	increased	HLA	class	I	intracellularly	even	in	U0126-
treated	samples,	whereas	PD-L1	protein	levels	were	decreased	in	all	cell	lines	tested	that	
showed	sensitivity	to	MEK-inhibition.		
The	effects	of	MEKi(s)	on	HLA	and	PD-L1	expression	were	consistent	in	the	cell	
lines	used	in	this	research,	with	Sel	and	Tram	generally	increasing	surface	HLA	class	I	and	
decreasing	PD-L1.	In	contrast,	U0126-mediated	effects	are	significantly	different	from	
the	others.	The	mechanism(s)	in	which	these	inhibitors	modulate	expression	needs	to	be	
addressed.		
			
4.2	MEKi-mediated	Effects	on	MDA-231c10A	
The	effects	of	MEK	inhibition	in	MDA-231c10A	differ	slightly	from	the	parent	line	
MDA-MB-231,	For	example,	although	U0126	decreased	HLA-DR,	HLA	class	I	and	PD-L1	in	
both	lines,	the	effect	on	HLA-DR	was	significant	for	c10A,	while	the	effect	on	HLA	class	I	
and	PD-L1	was	more	pronounced	in	MDA-MB-231.	Similarly,	Sel	and	Tram	treatment	
increased	HLA	class	I	and	decreased	PD-L1	in	both	lines,	but	the	effects	were	only	
significant	for	MDA-MB-231.	These	differential	effects	of	the	inhibitors	are	not	due	to	
technical	issues,	as	we	demonstrated	using	Western	blotting	that	all	inhibitors	
successfully	inhibited	phosphorylated	ERK	(Figure	3.1.	A	and	Figure	3.4.	A).	Due	to	these	
variations,	we	took	a	closer	look	at	the	differences	between	both	lines.		
MDA-231c10A	is	grown	in	estrogen-depleted	medium	and	differs	from	the	
parent	line	by	lacking	ERβ.	Although	previous	research	in	the	Drover	laboratory	showed	
that	estradiol	had	little	effect	on	HLA-DR	expression	in	U0126-treated	MDA-231c10A	
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cells77,	I	performed	a	preliminary	experiment	to	explore	whether	estradiol	altered	the	
effects	of	Sel	and	Tram	on	HLA	and	PD-L1	expression	in	c10A	cells	(Appendices		1	and	2).	
We	observed	limited	effects	of	estradiol	on	HLA	and	PD-L1	expression	in	MDA-231c10A	
cells,	however,	when	used	in	combination	with	either	Sel	or	Tram	the	effects	on	HLA	
class	I	and	HLA-DR	were	slightly	diminished.	While	no	differences	were	seen	in	PD-L1	
expression.	As	this	experiment	was	done	once,	it	is	hard	to	draw	any	conclusions,	
however	these	results	support	the	theory	that	both	Sel	and	Tram	alter	HLA	and	PD-L1	
expression	through	different	mechanisms,	which	could	help	explain	why	estradiol	
diminishes	inhibitor-mediated	effects	on	HLA	but	not	PD-L1.		
Although	Sel	and	PD98059	are	MEK	1-specific,	Sel	had	the	opposite	effect	as	PD-
L1	was	decreased	in	Sel-treated	MDA-231c10A	cells,	but	increased	with	PD98059	
treatment.	Similarly,	the	effects	on	HLA	and	PD-L1	by	the	pan	MEK	inhibitors,	Tram	and	
PD0325901,	were	not	analogous	to	those	mediated	by	U0126.	For	example,	Tram,	unlike	
U0126,	increased	HLA	class	I,	but	like	U0126	it	decreased	PD-L1	expression.	PD0325901	
has	almost	no	effect	on	HLA	and	PD-L1.	Because	of	these	variations,	we	queried	if	the	
mechanisms	employed	by	these	inhibitors	were	similar	for	some	molecules,	such	as	PD-
L1,	yet	varied	for	others	(HLA).	This	also	suggested	to	us	that	the	effects	of	the	MEKi(s)	
may	not	be	specifically	MEK	1-	or	MEK	2-dependent.	
It	is	currently	unclear	why	U0126	significantly	differs	from	the	other	MEKi(s)	in	its	
effects	on	HLA	and	PD-L1	modulation.	Although	a	pan	MEK	inhibitor,	the	reason	for	
differential	effects	might	be	seen	further	downstream	than	MEK	1/2.	As	ERK	1/2	are	the	
only	downstream	targets	of	MEK	activation	and	are	last	in	the	MAPK	pathway	(Chapter	
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1.5),	it	was	anticipated	that	by	knocking	down	ERK	1	and	ERK	2	using	small	interfering	
RNA,	we	might	better	understand	the	differential	effects	of	the	inhibitors.	Due	to	MDA-
231c10A	showing	moderate	levels	of	both	constitutive	HLA	class	I	and	PD-L1,	the	
experiments	were	done	in	the	absence	of	IFN-γ.	As	the	results	of	the	knockdowns	
compared	to	the	scrambled	control	siRNA,	were	not	significant,	we	determined	that	the	
inhibitor	mediated	effects	were	not	due	to	ERK	inactivation.	Furthermore,	it	would	have	
been	more	relevant	to	have	used	MEK-specific	siRNA	as	the	inhibitors	are	MEK-,	not	
ERK-specific	and	their	effects	might	only	be	induced	at	that	particular	point	in	the	MAPK	
pathway.	
	
4.3	MEKi-mediated	Effects	on	Other	TNBC	Lines	
To	determine	whether	the	effects	of	MEKi(s)	on	HLA	and	PD-L1	in	MDA-231c10a,	
were	specific	for	TNBC,	we	performed	the	same	treatments	and	experiments	on	four	
additional	TNBC	lines.	If	the	effects	of	MEKi(s)	were	similar	in	other	lines	it	would	help	
determine	mechanistically	the	reason	for	altered	expression	of	HLA	and	PD-L1.	The	
mutations	in	each	cell	line	varies,	as	shown	in	Table	2.5:	MDA-MB-231	has	both	KRAS	
and	BRAF	mutations,	BT-20	has	a	PIK3CA	mutation,	MDA-MB-468	has	a	PTEN	mutation,	
and	HS578T	has	a	HRAS	mutation.	Tumours	that	carry	BRAF	mutations	have	been	shown	
to	be	more	sensitive	to	Sel	and	Tram83,89,90,91.	Due	to	the	BRAF	mutation	expressed	in	
MDA-MB-231,	we	hypothesized	that	Sel	and	Tram	would	have	similar	effects	on	HLA-DR	
expression	in	all	cell	lines	that	contained	this	mutation.	However,	we	found	that	the	
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effects	varied	among	the	cell	lines	with	BRAF	mutations,	whereas	U0126	consistently	
decreased	surface	expression.		
Both	Sel	and	Tram	increased	constitutive	and	induced	surface	HLA	class	I	
expression	in	MDA-MB-231	and	BT-20	despite	differences	in	mutations,	whereas	both	
had	no	effects	on	HLA	class	I	expression	in	HS578T.	The	limited	efficacy	in	HS578T	may	
be	due	to	a	high	threshold	in	this	cell	line	for	these	drugs,	as	some	cell	lines	require	
higher	concentrations.	This	was	shown	in	a	paper	by	Loi	and	colleagues	(2015)	that	large	
concentrations	of	Trametinib	were	needed	to	inhibit	phosphorylated	ERK	in	the	mouse	
tumor	lines	AT3ova	and	4T18.	This	potentially	high	threshold	for	Sel	or	Tram-mediated	
effects	on	HLA	class	I	in	HS578T	appeared	to	be	consistent	with	Western	blot	analysis,	
showing	that	lanes	with	Sel	and	Tram	incompletely	inactivated	phosphorylated	ERK	at	
the	72hr	time	point.		
The	effects	of	MEKi(s)	on	MDA-MB-468	show	stark	contrasts,	as	it	was	the	only	
cell	line	to	show	decreased	HLA	class	I	expression	with	inhibitor	treatment	other	than	
U0126.	Explanations	for	this	could	be	its	PTEN	mutation,	which	could	impact	the	
inhibitor-mediated	effects	as	links	between	the	loss	or	mutation	in	PTEN	and	the	
induction	of	PD-L1	has	been	reported	in	prostate	cancer	cells50,54.	A	future	direction	
would	be	to	explore	the	effects	of	PI3K	pathway	inhibition	on	HLA	and	PD-L1	expression	
in	MDA-MB-468	cells.		
In	MDA-MB-231	and	BT-20,	Sel,	Tram	and	U0126	decreased	both	constitutive	
and	induced	surface	PD-L1	and	protein	levels	seen	in	Western	blots.	Despite	different	
mutations,	both	cell	lines	have	similar	responses	to	the	inhibitors.	Western	blots	are	
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consistent	with	flow	cytometric	analysis,	which	indicates	the	inhibitors	are	decreasing	
both	surface	and	intracellular	protein	levels.	This	suggests	the	inhibitors	are	not	trapping	
PD-L1	intracellularly	as	may	be	the	case	with	HLA.		
		
4.4	MEKi-mediated	Effects	on	Non-BC	Lines	
To	determine	if	the	MEKi-mediated	effects	on	HLA	and	PD-L1	expression	were	
common	to	cancers	other	than	breast,	we	included	two	lines,	MDA-MB-435	and	HT-29,	
which	also	have	dysregulated	MAPK	pathways.	MDA-MB-435	has	a	BRAF	mutation,	and	
despite	some	confusion	in	the	literature	as	to	the	source	from	which	this	line	was	
originally	derived,	it	is	now	commonly	accepted	as	a	melanoma	line87.	HT-29	is	an	
adenocarcinoma	colon	cancer	line	also	containing	a	BRAF	mutation87.	
		 In	MDA-MB-435,	U0126	consistently	decreased	surface	HLA-DR,	HLA	class	I	and	
PD-L1	expression,	whereas	Sel	and	Tram	both	increased	HLA	class	I	expression	and	
decreased	PD-L1	as	was	seen	in	MDA-MB-231	and	BT-20.	The	effects	on	MDA-MB-435	
are	seen	in	both	constitutively	and	IFN-γ	induced	cells.	In	HT-29,	MEK	inhibition	with	Sel	
and	Tram	similarly	increased	HLA	class	I	and	decreased	PD-L1	expression.	Western	
blotting	analysis	on	these	lines	confirmed	results	seen	from	flow	cytometry	with	a	
decrease	in	PD-L1	expression	at	the	protein	level.	Interestingly,	as	was	the	case	with	the	
BC	lines,	HLA	class	I	protein	was	not	diminished	with	U0126	treatment,	despite	being	
decreased	on	the	surface.	The	increase	in	protein	HLA	class	I	in	cell	lines	treated	with	
both	Sel	and	Tram	are	consistent	with	surface	expression	via	flow	cytometry.	This	effect	
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is	not	novel,	and	it	has	been	documented	in	the	literature,	however	mechanisms	
regarding	altered	expression	are	still	unknown8.	
	
4.5	Mechanisms	
The	mechanism	through	which	U0126	down-regulates	HLA-DR	has	not	been	fully	
elucidated,	however,	in	previous	Western	blot	and	immunofluorescence	analysis	of	
MDA-231c10A	cells,	intracellular	levels	of	HLA-DR	were	not	decreased,	nor	were	they	
reduced	at	transcriptional	levels	as	shown	by	RT-PCR77.	Decreased	surface	HLA-DR	
expression	despite	abundant	levels	of	intracellular	HLA-DR	proteins	could	be	due	to		
disruption	in	trafficking	or	recycling	where	U0126,	either	through	a	MEK-dependent	or	
off-target	mechanism,	mediates	trapping	of	HLA-DR	in	endosomal	vesicles92.	To	further	
explore	this	potential	mechanism,	additional	immunofluorescence	analyses	using	
markers	for	HLA-DR	and	specific	endosomes	were	performed,	but	did	not	allow	any	
clear	conclusions	(data	not	shown).	Complicating	this	further	was	our	finding	that	
additional	MEK	inhibitors	had	variable	effect(s)	on	HLA-DR	in	all	cells,	regardless	of	MEK-
specific	targets.	These	data	indicate	that	mechanistically,	U0126	modulates	HLA-DR	
expression	differently	than	the	others.	
HLA	class	I	down-regulation	in	U0126-treated	cells	is	not	novel;	Robertson	and	
colleagues	(2006)	showed	U0126-mediated	decreased	surface	HLA	class	I	expression	in	
HeLa	cells,	however	increased	intracellular	pools	of	“trapped”	HLA	was	seen	in	the	
treated	cells92.	As	U0126	shows	similar	effects	of	down-regulation	of	both	HLA-DR	and	
HLA	class	I,	it	hints	that	the	mechanism	employed	for	down-regulation	is	similar	for	both	
	 113	
molecules	with	our	results	reinforcing	the	potential	trafficking	mechanism	employed	by	
U012677,92.	Since	the	start	of	this	thesis	project,	the	increase	in	surface	levels	of	HLA	
class	I	through	treatment	with	Sel	and	Tram	has	been	documented	in	the	literature,	with	
Loi	and	colleagues	(2015)	showing	that	treatment	with	Sel	and	Tram	greatly	increased	
constitutive	and	induced	surface	HLA	class	I	expression	in	mouse	model	lines	of	breast	
cancer8,	whereas	Liu	et	al	(2015)	showed	increases	through	treatment	with	both	Tram	
alone	or	in	combination	with	the	BRAF	inhibitor	Dabrafinib	in	human	melanoma	lines93.	
Liu	and	colleagues	found	this	increase	was	associated	with	increases	in	apoptotic	
markers	as	well	as	down-regulation	of	immunosuppression	factors.	Additionally,	Hu-
Lieskovan	and	colleagues	(2015)	also	saw	increases	in	HLA	class	I	through	MEK	inhibition	
with	Tram	treatment	in	a	mouse	BRAF	V600E	melanoma	model94.	Due	to	the	general	
agreement	that	down-regulation	of	HLA	class	I	leads	to	poorer	prognosis	and	tumor	
escape26,95,	these	results	indicate	increased	chance	of	tumor	destruction	and	decreased	
growth	via	treatment	with	MEK	inhibitors.	Incidentally,	when	observing	micro	dissected	
tumour	regions,	Garrido	and	colleagues	(2012)	showed	that	high	levels	of	HLA	class	I	
gene	expression	could	be	observed	in	regression	but	not	in	progressing	metastasis95.	
This	finding	supports	that	modulations	in	HLA	class	I	on	tumour	cells	could	have	
therapeutic	effects96.	Since	hyperactivation	of	MAPK	allows	cells	to	proliferate	
uncontrollably,	it	may	be	that	negative	regulation	of	HLA	class	I	could	be	a	mechanism	
employed	by	MAPK	pathway-mutated	tumor	cells	to	escape	immune	surveillance.	
Therefore,	by	inhibiting	the	pathway,	HLA	class	I	expression	is	restored.	
	 114	
The	mechanism	by	which	MAPK	regulates	PD-L1	is	not	fully	understood.	
However,	PD-L1	is	transcriptionally	regulated	by	the	c-jun	protein47,	consequently	U0126	
works	by	functionally	antagonizing	AP-1	transcriptional	activity,	which	is	formed	by	c-jun	
and	c-fos70.	Therefore	U0126	may	interfere	with	PD-L1	at	the	transcriptional	level,	which	
is	supported	by	the	decreases	in	PD-L1	protein	levels	seen	in	Western	blots	of	whole	cell	
lysates	(WCL)	prepared	from	all	cell	lines	in	which	the	MEKi(s)	successfully	inhibited	
phosphorylated	ERK.	Decreases	in	transcriptional	PD-L1	activity	via	MEK	inhibition	has	
been	documented,	with	a	study	confirming	both	decreased	PD-L1	and	increased	HLA	
class	I	and	II	in	the	melanoma	lines	A375	and	sk-MEL-24	via	RT-PCR	and	flow93.		As	these	
decreases	in	PD-L1	are	also	observed	with	both	Sel	and	Tram	treatment,	the	mechanism	
for	decreased	expression	may	be	common	to	all	three	inhibitors.	However,	the	effects	of	
MEK	inhibition	on	PD-L1	expression	are	controversial	in	the	literature	with	some	articles	
citing	decreases	in	expression,	while	others	cite	large	increases.	Liu	et	al	(2015)	found	
treatment	with	Tram	decreased	surface	PD-L1	levels	in	human	melanoma	lines	both	in	
the	presence	and	absence	of	IFN-γ,	however	mRNA	levels	of	PD-L1	increased	steadily	
over	the	course	of	treatment.	This	group	also	found	that	once	cells	developed	resistance	
to	BRAF	inhibition,	PD-L1	levels	increased93.	A	study	by	Atef	and	colleagues	(2014)	
showed	that	Tram	treatment	decreased	PD-L1	levels,	however,	induction	with	IFN-γ	had	
the	potential	to	reverse	this	effect97.	Jiang	et	al	(2013)	also	confirmed	down-regulated	
PD-L1	expression	in	human	melanoma	cells	through	Tram	treatment.	Jiang’s	findings	
also	complimented	that	of	Liu	with	the	decreases	in	PD-L1	expression	combined	with	
increases	in	apoptotic	markers47.	In	a	conflicting	study,	Loi	and	colleagues	(2015)	found	
	 115	
increasing	surface	PD-L1	levels	with	Sel	and	Tram	treated	mouse	breast	tumor	lines8	and	
Hu-Lieskovan	et	al	(2015)	also	found	increases	in	PD-L1	expression	in	a	mouse	
melanoma	model	after	Tram	treatment94.		
	
4.6	How	Our	Findings	Compare	to	Literature	
Through	the	course	of	this	research,	our	findings	are	synonymous	with	some	
literature	regarding	the	MEKi-mediated	effects	of	HLA	and	PD-L1	expression,	but	there	
are	some	conflicting	reports.	The	effects	of	U0126-treatment	on	HLA	class	I	expression	
in	all	cell	lines	is	in	agreement	with	Robertson	and	colleagues	(2006)	report	of	decreased	
expression	in	HeLa	cells,	as	well	with	previous	research	from	the	Drover	laboratory77,92.	
The	increase	of	HLA	class	I	through	treatment	with	Sel	and	Tram	is	in	agreement	with	
the	studies	mentioned	above8,94,98.	Our	results	were	consistent	both	in	the	presence	and	
absence	of	IFN-γ,	which	is	in	agreement	with	several	studies8,98.	However,	this	is	not	in	
agreement	with	Atefi	and	colleagues	(2014)43.			
Our	research	has	shown	repeatedly	that	MEK	inhibition	decreases	both	surface	
expression	and	protein	levels	of	PD-L1.	These	data	are	in	agreement	with	some	in	the	
literature93,97,47,	but	are	in	disagreement	with	others8,94.	It	is	worth	noting	that	the	
concentrations	of	Tram	used	in	the	conflicting	paper	by	Loi	and	colleagues	is	much	
higher	than	what	we	use8,	however	experiments	testing	minor	as	well	as	log	fold	
changes	in	concentrations	did	not	perceptibly	alter	our	findings	(appendices	3,4,	8	&	9).	
Even	at	concentrations	well	beyond	that	of	clinical	relevance,	we	demonstrated	that	
neither	Sel	or	Tram	increased	PD-L1	expression	in	our	TNBC	or	non-TNBC	lines.		
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The	conflicting	studies	regarding	MEK	inhibition	on	PD-L1	expression	could	be	
cell	context	dependent,	including	inhibition-resistant	lines,	species	variations	(human	
lines	or	mouse	lines),	as	well	as	the	cross-talk	present	between	the	MAPK	pathway	and	
others	such	as	PI3K/AKT,	and	although	marketed	as	specific	for	MEK,	these	inhibitors	
could	have	off	target	effects.	Human	breast	tumours	could	also	be	modified	the	tumour	
stage,	genetic	background	as	well	as	the	cell	milieu	in	the	tumour	microenvironment	
64,97,99,100	
	
4.7	Research	Limitations	
	 Despite	careful	attention	to	planning	and	executing	this	study,	we	
recognize	that	there	are	some	limitations	that	make	it	difficult	to	draw	firm	conclusions	
concerning	the	effects	of	MEKi	on	expression	of	HLA	and	PD-L1	in	TNBC.		Our	study	used	
eight	human	cell	lines,	a	relatively	small	number,	thus,	additional	lines		would	have	
increased	the	accuracy	of	our	findings,	especially	as	they	pertain	to	the	TNBC	lines.	In	
that	regard,	it	would	also	have	been	informative	to	increase	the	number	of	other	BCCL,	
such	as	ER+	and	HER2+	cell	lines	to	more	clearly	establish	whether	the	modulating	
effects	of	MEKi	on	HLA	and	PD-L1	were	specific	for	TNBC.	We	also	found	that	siRNA	did	
not	completely	knock	down	ERK	1	and	ERK	2,	as	there	were	small	amounts	of	ERK	
proteins	still	visible	in	the	lanes	containing	samples	treated	with	the	siRNA	(Figure	3.6	
A).	Indeed,	the	knockdowns	with	the	chemical	MEKi	were	more	complete	as	pERK	was	
barely	present	in	most	lines	treated	with	the	various	inhibitors.	Therefore,	it	would	have	
been	more	informative	to	knock	down	MEK	1	and	MEK	2	and	to	include	antibodies	that	
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were	also	specific	for	MEK	1	and	MEK	2.	There	were	also	some	issues	with	the	
antibodies	used	for	Western	blotting,	with	some	showing	non-specific	bands	and	high	
amounts	of	background,	as	well	as	disruptions	due	to	antibodies	that	were	discontinued	
during	the	course	of	our	research.	As	the	clinically	relevant	inhibitors	used	were	
relatively	new	during	the	course	of	this	research,	the	concentrations	suggested	by	the	
manufacturers	changed	multiple	times	depending	on	new	literature	published.	Another	
apparent	limitation	is	the	use	of	only	cell	lines,	but	analyzing	tissues	from	tumour	
biopsies	taken	before	and	after	treatment	with	MEKi,	is	beyond	the	scope	of	this	
Master’s	thesis.	Access	to	a	tumour	bank	and	human	tissue	samples	could	help	show	the	
real-world	relevance	of	our	work	to	human	breast	cancer	patients. 
	
4.8	Future	directions	
Future	directions	for	this	research	should	be	centered	on	understanding	the	
underlying	mechanisms	responsible	for	the	altered	expression	of	HLA-DR,	HLA	class	I	
and	PD-L1	via	MEKi(s).	Once	the	mechanisms	are	elucidated,	a	greater	understanding	of	
tumour	cell/T	cell	interactions	within	the	tumour	environment	can	be	gained	as	well	as	
information	regarding	potential	new	opportunities	for	combination	treatments	between	
pathway	inhibitors	and	other	treatments.		
The	effect	of	MEK	inhibition	on	tumour-infiltrating	T	cells	must	also	be	
addressed;	Previous	studies	have	shown	MEK	inhibitors	to	be	immunosuppressive	in	
vitro101,	however	Liu	and	colleagues	(2015)	found	that	Tram-treated	melanoma	cells	
resulted	in	a	partial/transient	inhibition	in	T	cell	proliferation,	but	when	treated	with	a	
combination	of	Tram	and	anti	PD-1,	TIL	levels	increased98.	Also,	Loi	et	al	(2015)	
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suggested	that	MEK	inhibitors	can	help	recruit	TILs8.	This	shows	that	the	effects	of	MEK	
inhibition	on	immune	cells	is	complex	and	context-dependent93.	
Future	directions	should	also	include	RT-PCR	to	test	whether	transcription	of	PD-
L1	is	affected	by	MEK	inhibition	in	TNBC	cells,	as	this	will	help	to	understand	the	
mechanism(s)	underlying	inhibitor-mediated	decreases.	As	there	exists	discrepancies	in	
MEK-inhibition	on	PD-L1	expression	between	studies	using	in	vivo	versus	in	vitro	
models8,98,	the	use	of	in	vivo	TNBC	models	should	be	assessed	to	determine	is	the	
effects	seen	in	human	lines	can	be	translated	to	animal	models.		
	
4.9	Significance	
	 The	potential	to	modulate	the	expression	of	immune	markers	on	tumour	cells	
could	prove	to	be	therapeutically	beneficial	for	those	with	treatment-limited	cancers,	
such	as	TNBC.	Through	hyperactivation	of	the	MAPK	pathway,	cell	growth	and	
proliferation	go	unchecked,	leading	to	tumour	growth	and	metastasis6,8,74,97.	Included	in	
this	rampant	cellular	proliferation,	immune-escape	mechanisms	are	also	employed	to	
down-regulate	antigen	presenting	markers	such	as	HLA	class	I26.	Through	inhibition	of	
the	MAPK	pathway,	the	ability	to	increase	surface	HLA	class	I	could	aid	in	growth	
inhibition	and	tumour	destruction.	In	addition	to	the	increase	in	antigen	presenting	
markers,	the	decreased	expression	of	inhibitory	molecules	such	as	PD-L1	could	
exaggerate	the	chances	of	tumour	destruction	through	decreased	T	cell	inhibition	and	
activation.		
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	 Selumetinib	is	currently	being	tested	in	20	ongoing	clinical	trials70;		and	
Trametinib	is	already	FDA-approved	in	combination	with	an	AKT	inhibitor	for	the	
treatment	of	melanoma70,86,90,102.	With	our	results	with	Sel	and	Tram	consistently	
increasing	HLA	class	I	and	decreasing	PD-L1	levels	across	multiple	cell	lines,	there	exists	
the	possibility	that	these	drugs	may	also	have	therapeutic	benefits	in	TNBC.		
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Appendix	1:	Flow	cytometric	analysis	showing	treated/untreated	values	of	MDA-
231c10A	cells	treated	with	E2	in	combination	or	absence	of	Selumetinib.		
Cells	were	treated	with	Selumetinib	(15	nM)	with	DMSO	as	a	vehicle	control,	E2	(109M)	
in	combination	with	or	alone	with	ethanol	as	vehicle	control,		for	72	hours	and	then	with	
IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	determine	A)	Surface	HLA-DR	(L243)	
expression.	B)	Surface	HLA	class	I	(W6/32)	expression.	C)	Surface	PD-L1	(MIH2)	
expression.	
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Appendix	2:	Flow	cytometric	analysis	showing	treated/over	untreated	values	of	MDA-
231c10A	cells	treated	with	E2	in	combination	or	absence	of	Trametinib.		
Cells	were	treated	with	Trametinib	(2	nM)	with	DMSO	as	a	vehicle	control,	E2	(109M)	in	
combination	with	or	alone	with	ethanol	as	vehicle	control,		for	72	hours	and	then	with	
IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	determine	A)	Surface	HLA-DR	(L243)	
expression.	B)	Surface	HLA	class	I	(W6/32)	expression.	C)	Surface	PD-L1	(MIH2)	
expression.	
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Appendix	3:	Flow	cytometric	analysis	of	concentration	experiment	with	MDA-231	c10A	
treated	with	Selumetinib	(15	nM,	25	nM	or	50	nM),	or	DMSO	(vehicle	control),	induced	
with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	a	total	incubation	time	of	72	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	4:	Flow	cytometric	analysis	of	concentration	experiment	with	MDA-231	c10A	
treated	with	Trametinib	(2	nM,	5	nM	or	10	nM),	or	DMSO	(vehicle	control),	induced	with	
IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	a	total	incubation	time	of	72	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	5:	Flow	cytometric	analysis	of	concentration	experiment	with	MDA-231	c10A	
treated	with	PD0325901	(0.5	nM,	1	nM,	or	5	nM),	or	DMSO	(vehicle	control),	induced	
with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	for	a	total	incubation	time	of	72	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	6:	Flow	cytometric	analysis	of	time	course	experiment	with	MDA-231	c10A	
treated	with	Selumetinib	(15	nM),	or	DMSO	(vehicle	control),	induced	with	IFN-γ	(100	
u/ml)	1hr	after	MEKi	treatment	for	total	incubation	time(s)	of	6,	24,	&	48		hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	7:	Flow	cytometric	analysis	of	time	course	experiment	with	MDA-231	c10A	
treated	with	Trametinib	(2	nM),	or	DMSO	(vehicle	control),	induced	with	IFN-γ	(100	
u/ml)	1hr	after	MEKi	treatment	for	total	incubation	time(s)	of	6,	24,	&	48	hours	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	8:	Flow	cytometric	analysis	of	log	dosage	experiment	with	Selumetinib-
treated	MDA-231	c10A	cells.	
Cells	were	treated	with	Selumetinib	(15	nM,	1500	nM	or	15000	nM),	or	DMSO	(vehicle	
control)	for	72	hours	and	then	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
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Appendix	9:	Flow	cytometric	analysis	of	log	dosage	experiment	with	Trametinib-treated	
MDA-231	c10A.	
Cells	were	treated	with	Trametinib	(2	nM,	200	nM	or	2000	nM),	or	DMSO	(vehicle	
control)	for	72	hours	and	then	with	IFN-γ	(100	u/ml)	1hr	after	MEKi	treatment	to	
determine	A)	Surface	HLA-DR	(L243)	expression.	B)	Surface	HLA	class	I	(W6/32)	
expression.	C)	Surface	PD-L1	(MIH2)	expression.	Experiment	shown	was	done	once.	
	
	
